Premier Alternatives

Adcendo

Drug Discovery · Frederiksberg, Denmark · Founded 2017 · Privately Held (backing)

Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. Adcendo is based in Frederiksberg, Denmark and was founded in 2017. It was valued at $210 million at its later-stage round in Nov 2024, the last priced event on record. It has raised $316 million across 2 recorded rounds; the latest was a $134 million Series B in Nov 2024.

PMV mark · valuation
$209.9M
Oct 2026
Priced at
its later-stage round
Nov 2024
Total raised
$315.9M
Last round
Later Stage VC (Series B)
Nov 2024

Adcendo key facts

as of Oct 2026
  • Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs.
  • Adcendo is valued at approximately $209.9M as of Oct 2026, set at its later-stage round, Nov 2024; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $315.9M across 2 recorded rounds; the latest was Later Stage VC (Series B) ($134.1M) in Nov 2024.
  • Notable investors include Bpifrance, RA Capital Management, OrbiMed, InnoFounder, Novo Holdings — 21 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$209.9M

Valued at $209.9M at its later-stage round, Nov 2024. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Adcendo with a free account
  • ·The complete investor list: 21 names
  • ·Watch Adcendo: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Adcendo funding rounds

2 rounds
Nov 2024Later Stage VC (Series B)$134.1M▮
Apr 2023Later Stage VC (Series A)$105.2M▮
Full funding history →

Adcendo valuation

Adcendo was valued at $210 million at its later-stage round in Nov 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Adcendo raised?

Adcendo has raised $316 million in total; 2 of its rounds are on record. The largest on record was a $134 million Series B in Nov 2024.

Adcendo investors

21 investors are on record for Adcendo, including Bpifrance, RA Capital Management, OrbiMed and InnoFounder. The Series B in Nov 2024 drew 11 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Adcytherix ($213 million), Plexium ($200 million) and Ajax Therapeutics ($193 million).

About Adcendo

Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. The company's conjugates are directed at a target receptor, which is an approach that helps targeted therapy in several cancer forms where expression of the target is unregulated, including soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, enabling doctors to treat patients with diseases such as carcinomas, breast, colon, pancreatic, prostate, ovarian, and renal cancers.

Industry
Drug Discovery
Sector
Healthcare
HQ
Frederiksberg, Denmark
Founded
2017
Employees
60
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.